Purpose: This study aimed to determine the minimum inhibitory concentrations (MICs) of ertapenem on collected from eight Chinese provinces in 2018.
Methods: The MICs of ertapenem on 503 isolates (415 isolates selected randomly and 88 isolates selected with preference) were measured using the agar dilution method. For comparison, the MICs of ceftriaxone and azithromycin were detected.
Results: Among 415 randomly selected isolates, the MIC range for ertapenem was from ≤0.008 mg/L to 0.5 mg/L. The corresponding MIC and MIC were 0.06 and 0.125 mg/L, respectively. Twelve of 415 isolates (2.9%) exhibited MIC values ≥0.25 mg/L, and only one isolate (0.2%) had a MIC of 0.5 mg/L. By comparing all 503 tested isolates, a correlation of = 0.487 ( <0.001) between ertapenem and ceftriaxone MIC was observed, and the correlation between MICs of ertapenem and azithromycin was low ( = -0.12, = 0.007). In 24 ceftriaxone-decreased susceptibility isolates, four isolates (16.7%) showed a MIC ≥0.25 mg/L for ertapenem. In 85 azithromycin resistant isolates, three isolates (3.5%) showed a MIC ≥0.25 mg/L for ertapenem.
Conclusion: The in vitro results suggest that ertapenem has satisfactory susceptibility in isolates collected from eight provinces in China; hence, it might be a promising treatment option for resistant gonococcal infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520434 | PMC |
| http://dx.doi.org/10.2147/IDR.S335252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of genotypic features between two groups of antibiotic resistant Klebsiella pneumoniae clinical isolates obtained before and after the COVID-19 pandemic from Egypt.
BMC Genomics
October 2024
Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, 1 Khartoum Sq, Alexandria, 21521, Egypt.
Klebsiella pneumoniae is a common pathogen capable of causing a wide range of infections. Antibiotic resistance complicates treatment of these infections significantly. We are comparing resistance levels and genotypes among two collections of K.
View Article and Find Full Text PDFIn vitro activity of cefepime-enmetazobactam on carbapenem-resistant gram negatives.
Clin Microbiol Infect
October 2024
Team "Resist" UMR1184 "Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB)", INSERM, Université Paris-Saclay, CEA, LabEx LERMIT, Le Kremlin-Bicêtre, France; Bacteriology-Hygiene Unit, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France; Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacteriaceae, Le Kremlin-Bicêtre, France. Electronic address:
Article Synopsis
- Cefepime-enmetazobactam is a new antibiotic combination that effectively targets multidrug-resistant Enterobacterales, including ESBL producers, and was tested against various resistant bacteria.
- The study evaluated the minimum inhibitory concentration (MIC) of cefepime-enmetazobactam compared to other antibiotic combinations on over 2,200 strains of carbapenem-resistant Enterobacterales and other pathogens.
- Results showed that while cefepime-enmetazobactam had good activity against OXA-48 producers, it offered no significant advantage over cefepime alone in treating Pseudomonas aeruginosa and Acinetobacter baumannii, highlighting the need for further in vivo testing.
Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality.
J Antimicrob Chemother
December 2024
Infectious Disease Unit, Edith Wolfson Medical Center, Holon, Israel.
Background: Recently, breakpoints of Enterobacterales to amikacin were changed from MIC ≤ 16 mg/L to MIC ≤ 4 mg/L based mainly on laboratory data with little supporting clinical evidence. Our aim was to investigate the relation between MIC of Enterobacterales to amikacin and mortality among patients with Enterobacterales bacteraemia from a urinary tract source treated with amikacin.
Patients And Methods: This retrospective, single-centre study included patients with Enterobacterales urinary source bacteraemia treated with amikacin, with Low (MIC ≤ 4 mg/L) and High (MIC 8 or 16 mg/L) MICs.
Development and validation of a pentaplex PCR assay for rapid detection of bla bla, bla bla and the PBP3 insert in Enterobacterales.
Indian J Med Microbiol
December 2024
Department of Clinical Microbiology, Christian Medical College, Vellore, India. Electronic address:
Background: There is a high diversity of beta-lactamases in gram negative pathogens, making them difficult to treat. In the presence of OXA-1 and ampC, PTZ is no longer clinically relevant when treating Enterobacterales expressing ESBLs. Further, MBL infections are often treated with the combination of ceftazidime/avibactam with aztreonam.
View Article and Find Full Text PDFInfluence of Kidney Environment Parameters on Antibiotic Efficacy Against Uropathogenic Escherichia coli.
Eur Urol Focus
September 2024
Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University of Giessen, Giessen, Germany; German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Giessen, Germany.
Article Synopsis
- Urinary tract infections (UTIs) are commonly caused by bacteria, particularly Escherichia coli, with kidney infections (pyelonephritis) being severe and difficult to treat due to the unique kidney microenvironment.
- The study tested how factors like sodium chloride, urea, and pH levels affect the effectiveness of antibiotics (ertapenem, levofloxacin, and ceftriaxone) against E. coli strains in conditions mimicking the kidney.
- Findings showed that pH significantly affects levofloxacin's effectiveness, while sodium chloride and urea impact various strains differently, highlighting the need for more research on other antibiotics and kidney conditions for better treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!